Interview: Luis Almeida, CEO, Luzitin, Portugal
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Luzitin, S.A. is an early-stage pharmaceutical company focused on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases, thus contributing to the human wellness.
Luzitin emerged as a spin-off company from an R&D partnership between Bluepharma, S.A. and the University of Coimbra, Portugal. The Luzitin’s starting intellectual property is a series of new photosensitizing drugs licensed-in from the University of Coimbra. In March 2011, these new photosensitizers have been awarded the INVENTA Prize, which honoured the most relevant Portuguese invention of the 2001-2010 decade.
Luzitin’s shareholders are Bluepharma, S.A., a venture capital firm (Portugal Ventures, S.A.), and the inventors of the patented drugs. Luzitin’s headquarters are located at S Martinho do Bispo, Coimbra, Portugal. Luis Almeida, MD, PhD (Chief Executive Officer), Luis Arnaut, PhD (Chief Scientific Officer), and Sérgio Simões, PharmD, PhD (Chairman), compose the Management Team (MT). All have over 20 years of experience in their fields, and altogether they cover all disciplines involved in drug R&D from bench to bedside.
Luzitin’s long-term goal is to become a leader in PDT or PDx of cancer and other selected indications by providing innovative products and services, and partnering with other companies and public research institutions to bring new products to market.
Luzitin is committed to reach proof-of-concept clinical trials (phase II) and afterwards to negotiate licensing terms with a pharmaceutical company to further co-develop and co-market its compounds.
Contact:
Luzitin, SA
Edifício Bluepharma – Rua da Bayer – S. Martinho do Bispo
3045-016 Coimbra
PORTUGAL
Phone: +351 239 800 300
Fax: +351 239 800 333
www.luzitin.pt
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
José Carlos Machado, Vice President & Researcher at The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) speaks about Portugal’s excellent research capacity and the need…
José Aranda da Silva, General Manager of Formifarma Portugal, stresses the importance of market access, demonstrating added value for companies today, as well as the need for a revamp of…
Jose Pereira Leal, Group Leader Head of the Bioinformatics Unit at Instituto Gulbenkian de Ciencia, discusses the institute’s unique selling point, stating that, “researchers will continue to come and stay…
João Lobo Antunes, Founder of Institute of Molecular Medicine (IMM), Portugal gives his insights into Portugal’s strengths in science and technology, as well as his ambitions to grow IMM into…
Agustín Oleaga, Managing Director of DHL Supply Chain Portugal discusses the challenges of supply chain management as it relates to the life sciences industry in Portugal, and how the country’s…
António Donato, Vice President of Tecnimede Group, Portugal, discusses the Portuguese company’s internationalization and expansion process while highlighting the ways in which the Portuguese pharmaceutical environment must change in order…
Abel Vizeu Fernandes, Country Director at Kedrion Portugal discusses how national tenders for plasma-derived products opened the company up to more opportunities for growth in Portugal, as well as his…
Between Portugal’s two main distribution channels of hospitals and pharmacies, hospitals have suffered in particular. As the pharmaceutical industry’s largest customer, it has been critical for government to work with…
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Rui Carrington, CEO of OCP Portugual, a Pharmaceutical distributor which has undergone a significant evolution over the years as part of an adaptation to the changing market trends in Portugal,…
See our Cookie Privacy Policy Here
